Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma with BRAF V600 Mutation
Unresectable stage III and metastatic (stage IV) melanoma harbouring a BRAF V600 mutation represents a specific clinical setting in which the mutation status directly shapes the choice of treatment across lines of therapy.
Clinical Scenario
The confirmed presence of a BRAF V600 mutation in unresectable or metastatic melanoma is a defining feature of this population. Both BRAF inhibitor plus MEK inhibitor (BRAFi/MEKi) combination therapy and immune checkpoint inhibitors (ICIs) are relevant treatment classes in this setting, and the mutation status informs how therapy is sequenced across lines.
Treatment Approach
Management in this population involves a rechallenge strategy that draws on the targeted or immunotherapy drug class not used in the immediately preceding line — with additional options available when those classes are not accessible.
References
- In case of BRAF-mutated melanoma, additional first-line options are provided by BRAFis and MEKis.
- If anti-PD-1-based therapy is not available or patients are considered ineligible for its use, BRAFi–MEKi combination therapy (dabrafenib–trametinib [ESMO-MCBS v1.1 score: 5]; vemurafenib–cobimetinib [ESMO-MCBS v1.1 score: A/5]; binimetinib–encorafenib [ESMO-MCBS v1.1 score: A/5]) is also an option in the first line for patients with BRAF-mutated melanoma [I; A; ESCAT score: I-A].
- Third-line treatment rechallenge with the drug class (BRAFi–MEKi [IV, C] or ICI [IV, B]) not used in the immediate previous line can be considered, if feasible.
- If clinical trials, ICIs or BRAFis/MEKis are not available, chemotherapy may be administered as later-line therapy [IV, C], with modest activity and no impact on OS.
View source ↗